Home
BEAM
BEAM News

Latest Beam Therapeutics Inc. (BEAM) News on September 18, 2025

Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program

Simply Wall St.

4 days ago

Beam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 Program

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

Zacks

a month ago

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating

Insider Monkey

a month ago

JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating

3 Promising Genomics Stocks to Keep an Eye On in 2025

Zacks

3 months ago

3 Promising Genomics Stocks to Keep an Eye On in 2025

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Investor's Business Daily

3 months ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Investor's Business Daily

3 months ago

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

MT Newswires

3 months ago

Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial

GlobeNewswire

3 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Zacks

3 months ago

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks

3 months ago

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

GlobeNewswire

3 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

MT Newswires

4 months ago

Sector Update: Health Care Stocks Fall Pre-Bell Friday

FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy

Insider Monkey

4 months ago

FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy

MT Newswires

4 months ago

Beam Therapeutics Says US FDA Granted Orphan Drug Designation to BEAM-302

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire

4 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

GlobeNewswire

4 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

4 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire

4 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Zacks

4 months ago

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?

Simply Wall St.

4 months ago

Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Zacks

4 months ago

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

MT Newswires

4 months ago

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires

4 months ago

Beam Therapeutics Shares Fall After Q1 Net Loss Widens

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

Zacks

4 months ago

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire

4 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Beam Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks

5 months ago

Beam Therapeutics to Report Q1 Earnings: What's in the Cards?

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Investor's Business Daily

5 months ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

5 months ago

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Zacks

5 months ago

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Benzinga

5 months ago

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

GlobeNewswire

5 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

MT Newswires

5 months ago

RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

Insider Monkey

6 months ago

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

6 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

The Wall Street Journal

6 months ago

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Investing.com

6 months ago

Street Calls of the Week

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Zacks

6 months ago

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

MT Newswires

6 months ago

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires

6 months ago

BofA Securities Upgrades Beam Therapeutics to Buy From Neutral

MT Newswires

6 months ago

Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

GlobeNewswire

6 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

Zacks

6 months ago

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?

Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?

Insider Monkey

6 months ago

Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?

Biotech Alert: Searches spiking for these stocks today

TipRanks

6 months ago

Biotech Alert: Searches spiking for these stocks today

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Zacks

6 months ago

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

MT Newswires

6 months ago

Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?

Insider Monkey

6 months ago

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?

MT Newswires

6 months ago

Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein

Beam base editing therapy gets ‘proof of concept’ in rare lung disease

BioPharma Dive

6 months ago

Beam base editing therapy gets ‘proof of concept’ in rare lung disease

MT Newswires

6 months ago

Beam Therapeutics Prices $500 Million Share, Warrant Offering

Beam Therapeutics Announces Pricing of Underwritten Offering

GlobeNewswire

6 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

GlobeNewswire

6 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Benzinga

6 months ago

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Zacks

7 months ago

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

MT Newswires

7 months ago

RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk

Beam Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Beam Therapeutics Full Year 2024 Earnings: Beats Expectations

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Zacks

7 months ago

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

MT Newswires

7 months ago

Beam Therapeutics Swings to Q4 Loss as Revenue Falls

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

GlobeNewswire

7 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Cathie Wood buys $11 million of under-the-radar AI stock

TheStreet

7 months ago

Cathie Wood buys $11 million of under-the-radar AI stock

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

GlobeNewswire

7 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey

7 months ago

Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

7 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?

Zacks

7 months ago

Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Zacks

7 months ago

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

Simply Wall St.

8 months ago

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

GlobeNewswire

8 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

MT Newswires

8 months ago

Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet

Zacks

8 months ago

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Zacks

8 months ago

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Zacks

8 months ago

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire

8 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Investor's Business Daily

8 months ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Zacks

8 months ago

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

GlobeNewswire

8 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

9 months ago

Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?

Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

9 months ago

Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?

5 Biotech Breakthrough Stocks to Watch in 2025

Zacks

9 months ago

5 Biotech Breakthrough Stocks to Watch in 2025

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

9 months ago

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey

9 months ago

Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

Benzinga

9 months ago

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Zacks

9 months ago

Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

BioPharma Dive

9 months ago

ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug

MT Newswires

9 months ago

Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

9 months ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

9 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

MT Newswires

9 months ago

Beam Therapeutics Appoints Sravan Emany as CFO

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

GlobeNewswire

9 months ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Zacks

9 months ago

Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

GlobeNewswire

9 months ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

GlobeNewswire

10 months ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

MT Newswires

10 months ago

Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

TipRanks

10 months ago

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

MT Newswires

10 months ago

Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Zacks

10 months ago

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

MT Newswires

10 months ago

RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

10 months ago

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

Share on Social Networks: